These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 8270885)

  • 21. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.
    Plotnicky-Gilquin H; Robert A; Chevalet L; Haeuw JF; Beck A; Bonnefoy JY; Brandt C; Siegrist CA; Nguyen TN; Power UF
    J Virol; 2000 Apr; 74(8):3455-63. PubMed ID: 10729118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant forms of the F protein of human respiratory syncytial (RS) virus induce a cytotoxic T lymphocyte response but not a neutralizing antibody response and only transient resistance to RS virus infection.
    Gaddum RM; Cook RS; Wyld SG; López JA; Bustos R; Melero JA; Taylor G
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1239-48. PubMed ID: 8683212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.
    Cautivo KM; Bueno SM; Cortes CM; Wozniak A; Riedel CA; Kalergis AM
    J Immunol; 2010 Dec; 185(12):7633-45. PubMed ID: 21084664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory Syncytial Virus (RSV) Pulmonary Infection in Humanized Mice Induces Human Anti-RSV Immune Responses and Pathology.
    Sharma A; Wu W; Sung B; Huang J; Tsao T; Li X; Gomi R; Tsuji M; Worgall S
    J Virol; 2016 May; 90(10):5068-5074. PubMed ID: 26962219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of IL-12 treatment on vaccine-enhanced illness during infection with respiratory syncytial virus.
    Openshaw PJ; Hussell T
    Dev Biol Stand; 1998; 92():179-85. PubMed ID: 9554273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
    Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
    Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonreplicating vaccines can protect african green monkeys from the memphis 37 strain of respiratory syncytial virus.
    Eyles JE; Johnson JE; Megati S; Roopchand V; Cockle PJ; Weeratna R; Makinen S; Brown TP; Lang S; Witko SE; Kotash CS; Li J; West K; Maldonado O; Falconer DJ; Lees C; Smith GJ; White P; Wright P; Loudon PT; Merson JR; Jansen KU; Sidhu MK
    J Infect Dis; 2013 Jul; 208(2):319-29. PubMed ID: 23596321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Helper T cell recognition of respiratory syncytial virus in mice.
    Openshaw PJ; Pemberton RM; Ball LA; Wertz GW; Askonas BA
    J Gen Virol; 1988 Feb; 69 ( Pt 2)():305-12. PubMed ID: 2963089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recognition of respiratory syncytial virus fusion protein by mouse cytotoxic T cell clones and a human cytotoxic T cell line.
    Cannon MJ; Bangham CR
    J Gen Virol; 1989 Jan; 70 ( Pt 1)():79-87. PubMed ID: 2471784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus.
    Hussell T; Spender LC; Georgiou A; O'Garra A; Openshaw PJ
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2447-55. PubMed ID: 8887477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Building a better neonatal mouse model to understand infant respiratory syncytial virus disease.
    You D; Siefker DT; Shrestha B; Saravia J; Cormier SA
    Respir Res; 2015 Aug; 16(1):91. PubMed ID: 26231396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunity and immunopathology to respiratory syncytial virus. The mouse model.
    Openshaw PJ
    Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 2):S59-62. PubMed ID: 7551415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy.
    Bolger G; Lapeyre N; Dansereau N; Lagacé L; Berry G; Klosowski K; Mewhort T; Liuzzi M
    Can J Physiol Pharmacol; 2005 Feb; 83(2):198-213. PubMed ID: 15791294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.
    Graham BS; Bunton LA; Wright PF; Karzon DT
    J Clin Invest; 1991 Sep; 88(3):1026-33. PubMed ID: 1909350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BuShenYiQi Formula strengthens Th1 response and suppresses Th2-Th17 responses in RSV-induced asthma exacerbated mice.
    Wang J; Wu J; Kong L; Nurahmat M; Chen M; Luo Q; Li B; Wu X; Dong J
    J Ethnopharmacol; 2014 May; 154(1):131-47. PubMed ID: 24704667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.
    Johnson TR; Varga SM; Braciale TJ; Graham BS
    J Virol; 2004 Aug; 78(16):8753-60. PubMed ID: 15280483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness.
    Hussell T; Khan U; Openshaw P
    J Immunol; 1997 Jul; 159(1):328-34. PubMed ID: 9200470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.
    Buchholz UJ; Granzow H; Schuldt K; Whitehead SS; Murphy BR; Collins PL
    J Virol; 2000 Feb; 74(3):1187-99. PubMed ID: 10627529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.